These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27755102)

  • 1. HVTN100 phase 1/2 vaccine trial results promising; phase 2b/3 trial to commence.
    Harper KN
    AIDS; 2017 Jan; 31(2):N1-N2. PubMed ID: 27755102
    [No Abstract]   [Full Text] [Related]  

  • 2. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [AIDS vaccine].
    Sikorska EJ
    Pneumonol Alergol Pol; 1991; 59(3-4):146-52. PubMed ID: 1843911
    [No Abstract]   [Full Text] [Related]  

  • 6. How should the potency of HIV vaccine candidates be determined?
    Sheets R; Bean P
    Am Clin Lab; 2000; 19(8):23. PubMed ID: 11146989
    [No Abstract]   [Full Text] [Related]  

  • 7. [Vaccines against AIDS finally in sight? Vaccination campaigns in China and Uganda in preliminary stages].
    Wolf HJ
    Fortschr Med; 1995 Nov; 113(31):20, 22. PubMed ID: 8529980
    [No Abstract]   [Full Text] [Related]  

  • 8. [Promising results with the anti-HIV vaccine].
    Katlama C
    Presse Med; 2003 Jun; 32(21):964. PubMed ID: 12876523
    [No Abstract]   [Full Text] [Related]  

  • 9. [AIDS vaccine: who should be selected for the test?].
    Marcus U
    Fortschr Med; 1995 Nov; 113(32):16-7. PubMed ID: 8543269
    [No Abstract]   [Full Text] [Related]  

  • 10. First AIDS vaccine trials next year.
    Bateman C
    S Afr Med J; 2001 Aug; 91(8):622-3. PubMed ID: 11584770
    [No Abstract]   [Full Text] [Related]  

  • 11. IAVI begins trials of AIDS vaccine.
    Expert Rev Vaccines; 2003 Dec; 2(6):731. PubMed ID: 15282843
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS vaccines: back to 'plan A'.
    Check E
    Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
    [No Abstract]   [Full Text] [Related]  

  • 13. New hope for an AIDS vaccine.
    Robinson HL
    Nat Rev Immunol; 2002 Apr; 2(4):239-50. PubMed ID: 12001995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite snags and skepticism, Thai vaccine trial lumbers on.
    Padma TV
    Nat Med; 2004 Dec; 10(12):1267. PubMed ID: 15580234
    [No Abstract]   [Full Text] [Related]  

  • 17. Tim Tucker--Director of the South African AIDS Vaccine Initiative. Interviewed by Pam Das.
    Tucker T
    Lancet Infect Dis; 2003 Mar; 3(3):173-5. PubMed ID: 12614737
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-1 T-cell vaccines: evaluating the next step.
    Pantaleo G
    Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
    Chege GK; Burgers WA; Müller TL; Gray CM; Shephard EG; Barnett SW; Ferrari G; Montefiori D; Williamson C; Williamson AL
    Vaccine; 2017 Feb; 35(6):929-937. PubMed ID: 28069361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
    Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O
    J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.